Evidence map›Paper›PMID 38927289›Full record

ReviewBiology2024

Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside.

Palma Fedele, Anna Natalizia Santoro, Francesca Pini, Marcello Pellegrino, Giuseppe Polito, Maria Chiara De Luca, Antonietta Pignatelli, Michele Tancredi, Valeria Lagattolla, Alessandro Anglani and 3 more

Abstract readReview
In one paragraph

Review in Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Genomic alterations and their correlation with metabolic-related genes in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. The effect of immunonutritional support in patients undergoing surgery and adjuvant chemotherapy for lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Palma FedeleOncology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.ORCID 0000-0002-7437-4676
Anna Natalizia SantoroOncology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.
Francesca PiniOncology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.
Marcello PellegrinoPathology Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Giuseppe PolitoNuclear Medicine Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Maria Chiara De LucaRadiotherapy Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Antonietta PignatelliPalliative Care Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Michele TancrediRadiology Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Valeria LagattollaClinic Nutrition Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy.
Alessandro AnglaniRadiology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.
Chiara GuariniOncology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.
Antonello PintoOncology Unit, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy.
Pietro BraccialePneumology Unit, Ostuni Hospital, 72017 Ostuni, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer presents significant therapeutic challenges, motivating the exploration of novel treatment strategies. Programmed cell death (PCD) mechanisms, encompassing apoptosis, autophagy, and programmed necrosis, are pivotal in lung cancer pathogenesis and the treatment response. Dysregulation of these pathways contributes to tumor progression and therapy resistance. Immunonutrition, employing specific nutrients to modulate immune function, and metabolic reprogramming, a hallmark of cancer cells, offer promising avenues for intervention. Nutritional interventions, such as omega-3 fatty acids, exert modulatory effects on PCD pathways in cancer cells, while targeting metabolic pathways implicated in apoptosis regulation represents a compelling therapeutic approach. Clinical evidence supports the role of immunonutritional interventions, including omega-3 fatty acids, in augmenting PCD and enhancing treatment outcomes in patients with lung cancer. Furthermore, synthetic analogs of natural compounds, such as resveratrol, demonstrate promising anticancer properties by modulating apoptotic signaling pathways. This review underscores the convergence of immunonutrition, metabolism, and PCD pathways in lung cancer biology, emphasizing the potential for therapeutic exploration in this complex disease. Further elucidation of the specific molecular mechanisms governing these interactions is imperative for translating these findings into clinical practice and improving lung cancer management.

Indexed as

apoptosisimmunonutritionlung cancermetabolismprogrammed cell death

Identifiers

PMID38927289
PMCPMC11201027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.